BryoLogyx Inc., a privately-held, preclinical company developing a new class of drugs to enhance cancer immunotherapies, has appointed David Crockford to the new position of vice president of clinical development and logistics. Mr. Crockford joins BryoLogyx after more than 40 years at pharmaceutical and biotechnology companies, most recently at Neurotrope, where he served as vice president of Regulatory Affairs. “David brings extensive pharmaceutical development experience, a deep under...